75 /100
HIGH RISK
Score updated May 30, 2026

DRMA — Dermata Therapeutics, Inc. Dilution Risk Tracker

Track DRMA dilution risk with DilutionWatch's stock tracker. DilutionScore™ measures dilution risk across 5 factors — lower scores indicate higher risk of share dilution.

⚠️ Not financial advice. Do your own research before making any investment decisions.

🔔 Track DRMA — Get alerts when the score changes →

📊 Score Breakdown

📋 Offering Ability
60
💰 Cash Runway
40
📊 Float Risk
45
⚠️ Warrant Exposure
90
🔄Convertible Debt

🌦️ Dilution Forecast

⛈️
Warning
High probability of dilution event
58%
📜 Warrant Exercise 60%
• Massive warrant overhang: 135% of shares outstanding
• Warrant risk score very high (90/100)
🔁 Convertible Conversion 60%
• Major convertible overhang: 49% potential dilution
• Convertible risk score very high (85/100)
📉 Score Deterioration 50%
• Score rose 53 points recently (worsening)
• Score in HIGH risk zone (75/100)
🔔 Track DRMA — Get forecast alerts →

💹 Market Data

Market Cap$5.23M
Shares Outstanding4.02M
Float3.17M
Cash$6.95M
DebtN/A
Short InterestN/A

🏛 Institutional Holdings

7 institutional holders · 26.9K shares
#1 Clear Street Group Inc. 17.0K shares
#2 Bank of America Corporation 3.5K shares
#3 Barclays Plc 2.4K shares
+ 4 more holders Sign up free to view →

📉 Short Interest

Short Interest114.6K
Days to Cover2.2
% of Float3.6%
FINRA data as of May 15, 2026

📁 Recent SEC Activity

xbrl XBRL WARRANT Mar 31, 2026
xbrl XBRL CONVERTIBLE Dec 31, 2022
Form 4 INSIDER TRANSACTION Feb 17, 2026
13F-HR BENEFICIAL OWNERSHIP Dec 31, 2025
13F-HR BENEFICIAL OWNERSHIP Dec 31, 2025
Full SEC filing analysis available with free account

📰 Recent News

No recent news
Track DRMA Dilution Risk in Real-Time
Get instant alerts when SEC filings impact dilution risk. Free tier available.
Start Tracking DRMA — Free
Real-time SEC alerts DilutionScore™ tracking No credit card required
🔬 More Research for DRMA
📊 DRMA FDA Catalyst Timeline & Biotech Grade — BiotechSigns 📡 DRMA Signal Convergence & Dark Pool Activity — StonkWhisper 📄 DRMA Dilution Risk Analysis — Full In-Depth Report

Part of the Guerilla Finance research network. Cross-reference multiple data sources for better due diligence.